panitumumab
takeda,amgen
['triplet', 'triplete', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
triplete study by : folfoxiri-pani vs folfox-pani as 1l mcrc. orr 73 vs 76%, r0 rate 25 vs 29%. pfs 12.7 vs 12.3 months (all negative). triplet more toxic. #asco22 
Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine.